C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes

Biochemical Pharmacology
Victor A GaultPeter R Flatt


Glucose-dependent insulinotropic polypeptide has been proposed as a potential therapeutic for type 2 diabetes, however, efforts to bring forward this drug have been hindered due to its short circulating half-life. We have adopted a novel strategy to increase potency and prolong GIP action through C-terminal mini-PEGylation (GIP[mPEG]). In contrast to GIP, GIP[mPEG] was resistant to dipeptidylpeptidase-IV (DPP-IV) up to and including 24h. Both GIP[mPEG] and GIP concentration-dependently stimulated cAMP production (EC50 6.6 and 0.7 nM, respectively) and insulin secretion (p < 0.01 to p < 0.001) in pancreatic BRIN-BD11 cells. Acute injection of GIP[mPEG] together with glucose to high fat fed mice significantly lowered plasma glucose (p < 0.05) and increased plasma insulin responses (p < 0.05). Furthermore, GIP[mPEG] markedly lowered plasma glucose when administered 4-24h prior to a glucose load (p < 0.05). Daily administration of GIP[mPEG] for 20 days in high fat mice did not alter body weight, food intake or non-fasting plasma insulin, however, non-fasting plasma glucose concentrations were significantly lowered (p < 0.05). Moreover, glucose tolerance was significantly improved (p < 0.05) together with glucose-mediated plasma ins...Continue Reading


Jun 1, 1992·Stroke; a Journal of Cerebral Circulation·K YoshidaE F Ellis
Apr 1, 1971·Clinica Chimica Acta; International Journal of Clinical Chemistry·J F Stevens
Jul 1, 1970·The Journal of Physiology·J C BrownR A Pederson
Jul 20, 2001·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·W Creutzfeldt
Aug 7, 2003·Biochemical and Biophysical Research Communications·Victor A GaultFinbarr P M O'Harte
Sep 30, 2003·Diabetes Care·Daniel J Drucker
Jan 8, 2004·American Journal of Physiology. Endocrinology and Metabolism·Ke-Hong DingCarlos M Isales
May 6, 2004·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·M D'AntonioS Canali
Sep 11, 2004·Bioorganic & Medicinal Chemistry Letters·Roger LégerDominique P Bridon
Apr 18, 2007·Journal of Peptide Science : an Official Publication of the European Peptide Society·Alpeshkumar K MaldeEvans C Coutinho
May 15, 2007·Gastroenterology·Laurie L Baggio, Daniel J Drucker
May 19, 2007·Journal of Neuroscience Research·Jenny NybergPeter S Eriksson
Aug 11, 2007·Expert Opinion on Drug Safety·Jeffrey W Stephens, Stephen C Bain
Nov 6, 2007·Frontiers in Bioscience : a Journal and Virtual Library·Carolyn F DeaconJ J Holst
Dec 7, 2007·Best Practice & Research. Clinical Endocrinology & Metabolism·Brian D Green, Peter R Flatt


Jan 25, 2014·Obesity Research & Clinical Practice·Clare E CollinsPhilip J Morgan
Mar 23, 2012·Journal of the American Chemical Society·Mohammad RashidianMark D Distefano
Nov 20, 2014·Future Medicinal Chemistry·Claire GinnSteve Brocchini
May 5, 2011·Biochimica Et Biophysica Acta·Kalyana C VennetiChandralal M Hewage
Sep 15, 2009·Best Practice & Research. Clinical Endocrinology & Metabolism·Nigel Irwin, Peter R Flatt
Apr 4, 2016·Trends in Molecular Medicine·Brian FinanMatthias H Tschöp
Nov 26, 2011·European Journal of Pharmacology·Emilie FaivreChristian Hölscher
Apr 12, 2018·International Journal of Molecular Sciences·Yu-Wen YuYung-Hsiao Chiang
Jun 9, 2016·Reviews in the Neurosciences·Yanwei LiChristian Hölscher
Oct 19, 2017·Diabetic Medicine : a Journal of the British Diabetic Association·Victor A Gault
Sep 4, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Mehdi Bin SamadJ M A Hannan

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.